Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
- Response deadline
- Dec 23, 2027 Due in 432 days
- Date posted
- Nov 22, 2024
- Source
- Open notice
Description
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.
Classifications
- NAICS93.839
Documents (1)
- DownloadRFA-HL-26-020-Full-Announcement.htmltext/html429 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)Due Oct 9, 2028
- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)Due Jan 7, 2027
- NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)Due Jan 7, 2028
- Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)Due Jan 7, 2028
- Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)Due Dec 23, 2027
- Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)Due Nov 18, 2027